Event

1

• Event

2
Feeder Vessel Treatment

• Professor William Freeman
• Shiley Eye Center, UCSD
• Permanent President of the International Society
  of Ocular Infections
• Co-Chief of the Shiley Eye Center Retina Division

3
Feeder Vessel Treatment

• Product Vision A device that directs the
  application of off-the-shelf photodynamic
  pharmaceuticals, improving their performance for
  treating pathologies of retinal
  neovascularization, including macular
  degeneration therapy.
• Technology Whereas off-the-shelf photodynamic
  therapies can treat, in a gross manner,
  abnormalities, by targeting the feeder vessel of
  the neovascularization for closure, increased
  therapeutic efficacy can be obtained.

4
Feeder Vessel Treatment
5
Feeder Vessel Treatment

• Potential Market
• There are currently around 500,000 new cases of
  wet AMD per year.
• It is projected that over 1.8 Million adults will
  develop macular degeneration by 2010, and this is
  expected to increase to 2.9 million by 2020.

Sources Archives of Ophthalmology, 2004
6
Feeder Vessel Treatment

• Stage of Development A few early tests published
  in peer-reviewed journals
• IP Status PCT Application WO/034889
• Market StatusAvailable worldwide

7
Feeder Vessel Treatment

• Developmental Plan Requires some clinical
  development.
• Business Strategy
• Flexible - Could incubate the technology - with
  special attention paid to reimbursement issues -
  then possible sale as a product line to a big
  device company.
• Potential PI Roles Testing and evaluation

8

• UCSD TechTIPS 9500 Gilman Drive La Jolla, CA
  92093-0910
• Tel [phone] Fax [phone]
  invent_at_ucsd.edu
• http//invent.ucsd.edu